"Designing Growth Strategies is in our DNA"

Epithelial Ovarian Cancer – Pipeline Review, 2019

Region :Global | Report ID: FBI100108

 

Table of Content:

1. Introduction

1.1. ReportOverview

2. Epithelial Ovarian Cancer - Overview

3. Executive Summary

4. Epithelial Ovarian Cancer: Pipeline Assessment

4.1. By Stage ofDevelopment

4.2. By Route ofAdministration

4.3. By DrugClass

4.4. By MoleculeType

4.5. By TherapyArea / Indication

4.6. By Drug Target

4.7. By Sponsor

5. Epithelial Ovarian Cancer: Company & Drug Profiles

5.1. ClinicalStage

5.1.1. SPL-108 – SPLASH PHARMACEUTICALS, INC.

5.1.1.1. Company Overview

5.1.1.2. Product Description

5.1.1.3. R&D Status & Development Activities

5.1.1.4. Mechanism of Action

5.1.1.5. Molecule Type

5.1.1.6. Stage of Development

5.1.1.7. Indications

5.1.1.8. Route of Administration

5.1.1.9. Funding

5.1.2. ACELARIN (NUC-1031) – NuCana

5.1.2.1. Company Overview

5.1.2.2. Product Description

5.1.2.3. R&D Status & Development Activities

5.1.2.4. Mechanism of Action

5.1.2.5. Molecule Type

5.1.2.6. Stage of Development

5.1.2.7. Indications

5.1.2.8. Route of Administration

5.1.2.9. Funding

5.1.3. TSR-042 – TESARO, Inc.

5.1.3.1. Company Overview

5.1.3.2. Product Description

5.1.3.3. R&D Status & Development Activities

5.1.3.4. Mechanism of Action

5.1.3.5. Molecule Type

5.1.3.6. Stage of Development

5.1.3.7. Indications

5.1.3.8. Route of Administration

5.1.3.9. Funding

5.1.4. Others

5.2. Preclinical

5.2.1. Company Overview

5.2.2. Product Description

5.2.3. R&D Status & Development Activities

5.2.4. Mechanism of Action

5.2.5. Molecule Type

5.2.6. Indications

5.2.7. Route of Administration

5.2.8. Funding

6. Epithelial Ovarian Cancer: An Overview on Dormant & Discontinued Pipeline Candidates

6.1. Overview

6.2. Product Description

6.3. Reason for Discontinuation

7. Epithelial Ovarian Cancer: Additional Key Insights

7.1.Epidemiology Overview: Epithelial Ovarian Cancer

7.2. Current Market Scenario: Epithelial Ovarian Cancer Therapeutics

8. Epithelial Ovarian Cancer: News, Press Releases and Conference Details

Note:

1) This Table of Content is tentative and subject to change as the research progresses.

2) Please note that the drug candidates included as examples were in the pipeline when this TOC was designed and their status might have changed since then.

Consulting Services
    How will you benefit from our consulting services ?